{"id":49764,"date":"2022-10-18T18:02:16","date_gmt":"2022-10-18T16:02:16","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/pfizer-presents-scientific-advancements-in-infectious-disease-prevention-and-treatments-at-idweek-2022\/"},"modified":"2022-10-18T18:02:16","modified_gmt":"2022-10-18T16:02:16","slug":"pfizer-presents-scientific-advancements-in-infectious-disease-prevention-and-treatments-at-idweek-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/pfizer-presents-scientific-advancements-in-infectious-disease-prevention-and-treatments-at-idweek-2022\/","title":{"rendered":"Pfizer Presents Scientific Advancements in Infectious Disease Prevention and Treatments at IDWeek 2022"},"content":{"rendered":"
\n

\nData demonstrate diversity of vaccine and anti-infective portfolio and cutting-edge scientific approach to battling viral and bacterial infections<\/i>\n<\/p>\n

\nPresentations of interest include a late-breaking abstract with the first full data of the efficacy and safety of Pfizer\u2019s bivalent respiratory syncytial virus (RSVpreF) vaccine candidate in older adults; and new data regarding PAXLOVID\u2122 (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), including its effect on COVID-19-related hospitalizations and other medical visits<\/i>\n<\/p>\n

\nPfizer to host \u201cRSV Data and COVID Vaccine Commercial Update\u201d call with analysts at 4:30 p.m. (EDT) on October 20, 2022<\/i>\n<\/p>\n

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) will share data across its expansive infectious disease portfolio, including company-sponsored and collaborative research studies, spanning both licensed and investigational vaccines, and antibiotic and antiviral therapies at IDWeek 2022 held in Washington, D.C. October 19-23, 2022. Data from 35 abstracts involving Pfizer vaccines and anti-infective therapies will illustrate the diversity of the portfolio and the company\u2019s cutting-edge scientific approach. This will include a late-breaking presentation of the full data from its Phase 3 (NCT05035212) RENOIR<\/b> (R<\/span><\/b>SV vaccine E<\/span><\/b>fficacy study iN<\/span><\/b> O<\/span><\/b>lder adults I<\/span><\/b>mmunized against R<\/span><\/b>SV disease) clinical trial, investigating its bivalent RSV A and B, stabilized RSV prefusion F subunit vaccine candidate, RSVpreF, when administered to adults 60 years of age and older. These data will also be presented on October 20, 2022, to the U.S. Centers for Disease Control and Prevention\u2019s (CDC) Advisory Committee on Immunization Practices (ACIP).\n<\/p>\n

<\/a><\/p>\n

\n\u201cThe data presented at this year\u2019s IDWeek showcase the breadth of Pfizer\u2019s vaccine and therapeutic research and development portfolio and our continued commitment to working to overcome infectious diseases that still present a serious health risk,\u201d said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Scientific Officer, Vaccine Research and Development, Pfizer. \u201cWe look forward to both sharing our exciting data, as well as connecting with the scientific community to determine how we can continue to work to bring transformative solutions to thwart infectious diseases.\u201d\n<\/p>\n

\nThe research to be presented includes new insights on bacterial and viral infections, including Lyme disease and C. difficile<\/i>. Additionally, <\/i>presentations will include <\/i>Pfizer\u2019s licensed vaccine, PREVNAR 13\u00ae <\/sup>(Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), and its investigational vaccine candidates RSVpreF and Group B Streptococcus<\/i>, GBS6. Beyond vaccines, Pfizer is also presenting new data regarding PAXLOVID\u2122 (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), its authorized oral treatment for COVID-19.\n<\/p>\n

\nKey Pfizer sponsored, investigator-sponsored and collaborative research oral and poster presentations leveraging the depth of Pfizer\u2019s scientific advances include:\n<\/p>\n